Blackhawk Capital Partners LLC. Makes New Investment in Becton, Dickinson and Company (NYSE:BDX)

Blackhawk Capital Partners LLC. acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,091 shares of the medical instruments supplier’s stock, valued at approximately $928,000.

Other large investors have also modified their holdings of the company. State Street Corp boosted its stake in Becton, Dickinson and Company by 0.8% during the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock worth $3,364,096,000 after purchasing an additional 106,616 shares during the period. Geode Capital Management LLC raised its holdings in shares of Becton, Dickinson and Company by 1.8% in the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after buying an additional 111,101 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Becton, Dickinson and Company by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after buying an additional 460,440 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after acquiring an additional 673,568 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BDX has been the subject of a number of recent research reports. Piper Sandler increased their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Barclays increased their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $278.29.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares in the company, valued at approximately $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the transaction, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,544 shares of company stock worth $2,370,309 in the last quarter. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.3 %

NYSE:BDX opened at $230.40 on Tuesday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The stock has a fifty day moving average price of $232.96 and a two-hundred day moving average price of $233.25. The stock has a market capitalization of $66.16 billion, a price-to-earnings ratio of 38.27, a PEG ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.